These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22104703)

  • 1. Changes in serum runt-related transcription factor 2 levels after a 6-month treatment with recombinant human parathyroid hormone in patients with osteoporosis.
    Zhu W; Yang ML; Yang GY; Boden G; Li L
    J Endocrinol Invest; 2012 Jun; 35(6):602-6. PubMed ID: 22104703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
    Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
    Sturmer A; Mehta N; Giacchi J; Cagatay T; Tavakkol R; Mitta S; Fitzpatrick L; Wald J; Trang J; Stern W
    Clin Pharmacokinet; 2013 Nov; 52(11):995-1004. PubMed ID: 23719683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
    Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.
    Zhang L; Li L; Yang M; Xu K; Boden G; Yang G
    Osteoporos Int; 2013 Mar; 24(3):1107-12. PubMed ID: 22419369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y; Xuan M; Wang B; Yang J; Zhang H; Zhang XZ; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Liu ZM; Li CJ; Wu TF; Sheng ZY; Li PQ; Tong JC
    Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L; Yang M; Liu D; Guo C; Li L; Yang G
    Exp Clin Endocrinol Diabetes; 2012 Jun; 120(6):361-6. PubMed ID: 22639400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of recombinant human parathyroid hormone(1-84) in patients with postmenopausal osteoporosis: a prospective, open-label, single-arm, multicentre, observational cohort study of the effects of treatment on quality of life and pain--the PROPOSE study.
    Möricke R; Rettig K; Bethke TD
    Clin Drug Investig; 2011; 31(2):87-99. PubMed ID: 21155613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative Effect of rhPTH(1-84) on Bone Mineral Density and Trabecular Bone Score in Hypoparathyroidism and Postmenopausal Osteoporosis.
    Cipriani C; Pepe J; Silva BC; Rubin MR; Cusano NE; McMahon DJ; Nieddu L; Angelozzi M; Biamonte F; Diacinti D; Hans D; Minisola S; Bilezikian JP
    J Bone Miner Res; 2018 Dec; 33(12):2132-2139. PubMed ID: 30088838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ; Wang B; Yang J; Xuan M; Song LG; Li H; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Tong XC; Jia Y
    Chin Med J (Engl); 2009 Dec; 122(24):2933-8. PubMed ID: 20137477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
    Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
    Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].
    Zhang XZ; Song LG; Wang B; Yang J; Li H; Xuan M; Lei T; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Shen J; Liu ZM; Li CJ; Wu TF; Xie HB; Tong JC
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):662-6. PubMed ID: 20979784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
    Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
    Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a Multispecies Probiotic Supplement on Bone Health in Osteopenic Postmenopausal Women: A Randomized, Double-blind, Controlled Trial.
    Jafarnejad S; Djafarian K; Fazeli MR; Yekaninejad MS; Rostamian A; Keshavarz SA
    J Am Coll Nutr; 2017; 36(7):497-506. PubMed ID: 28628374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ALX 111: ALX1-11, parathyroid hormone (1-84) - NPS Allelix, PREOS, PTH, recombinant human parathyroid hormone, rhPTH (1-84).
    Adis International Ltd
    Drugs R D; 2003; 4(4):231-5. PubMed ID: 12848587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized controlled trial to compare the efficacy of cyclical parathyroid hormone versus cyclical parathyroid hormone and sequential calcitonin to improve bone mass in postmenopausal women with osteoporosis.
    Hodsman AB; Fraher LJ; Watson PH; Ostbye T; Stitt LW; Adachi JD; Taves DH; Drost D
    J Clin Endocrinol Metab; 1997 Feb; 82(2):620-8. PubMed ID: 9024265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA; Anastasilakis AD; Bratengeier C; Woloszczuk W; Papatheodorou A; Terpos E
    Osteoporos Int; 2012 Mar; 23(3):1171-6. PubMed ID: 21305266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
    Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
    Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Endogenous intact PTH is suppressed during Teriparatide (rhPTH 1-34) administration in postmenopausal women with established osteoporosis.
    Anastasilakis AD; Polyzos SA; Goulis DG; Slavakis A; Efstathiadou Z; Kita M; Koukoulis G; Avramidis A
    Endocr J; 2008 Jul; 55(3):613-6. PubMed ID: 18520104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.